BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type AGlobeNewsWire • 12/18/19
BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board MemberGlobeNewsWire • 12/16/19
BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology ProgramsGlobeNewsWire • 12/09/19
BridgeBio Pharma (BBIO) Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/06/19
BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type AGlobeNewsWire • 12/03/19
Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment OptionsGlobeNewsWire • 09/24/19
BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2 (LGMD2i) with new subsidiary ML Bio SolutionsGlobeNewsWire • 09/05/19
Adaptive Biotech and BridgeBio shares rocket higher on their first day of tradeMarket Watch • 06/27/19
